Loading…
Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology
The human immunodeficiency virus type 1 (HIV-1) is an infectious viral agent that gradually extinguishes the immune system, resulting in acquired immune deficiency syndrome (AIDS). The aim of this study was to construct an RNA-positive control based on armored (AR) RNA technology, using HIV-1 RNA as...
Saved in:
Published in: | Iranian biomedical journal 2018-11, Vol.22 (6), p.394-400 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2914-cef9253096057e3a1dedcd0c9eee1eb77c06153335fdccba7116d9f1cd78676f3 |
---|---|
cites | |
container_end_page | 400 |
container_issue | 6 |
container_start_page | 394 |
container_title | Iranian biomedical journal |
container_volume | 22 |
creator | Gholami, Mohammad Ravanshad, Mehrdad Baesi, Kazem Samiee, Siamak M. Hosseini Rozbahani, Negin Mohraz, Minoo |
description | The human immunodeficiency virus type 1 (HIV-1) is an infectious viral agent that gradually extinguishes the immune system, resulting in acquired immune deficiency syndrome (AIDS). The aim of this study was to construct an RNA-positive control based on armored (AR) RNA technology, using HIV-1 RNA as a model.
The MS2 maturase, a coat protein gene (at positions 1765 to 1787) and HIV-1 pol gene were cloned into pET-32a plasmid. The prepared plasmid was transformed into Escherichia coli strain BL2 (DE3), and the expression of the construct was induced by 1 mM of isopropyl-L-thio-D-galactopyranoside (IPTG) at 37 °C for 16 h to obtain the fabricated AR RNA. The AR RNA was precipitated and purified using polyethylene glycol and Sephacryl S-200 chromatography.
The stability of AR RNA was evaluated by treatment with DNase I and RNase A and confirmed by transmission electron microscopy and gel agarose electrophoresis. Tenfold serial dilution of AR RNA from 101 to 105 was prepared. Real-time PCR assays had a range of detection between 101 and 105. In addition, R2 value was 0.998, and the slope of the standard curve was -3.33.
Prepared AR RNA, as a positive control, could be used as a basis for launching an in-house HIV-1 virus assay and other infectious agents. It can be readily available to laboratories and HIV research centers. The AR RNA is non-infectious and highly resistant to ribonuclease enzyme and can reduce the risk of infection in the clinical laboratory. |
doi_str_mv | 10.29252/.22.6.394 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6305816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2041641250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2914-cef9253096057e3a1dedcd0c9eee1eb77c06153335fdccba7116d9f1cd78676f3</originalsourceid><addsrcrecordid>eNpVkU1LAzEQhoMoWqsXf4DkKMLWfHST7kWopdqCqNRaegtpMqsr201Ndgv990ZbRU8zk3nmnQkvQmeUdFjGUnbVYawjOjzr7qEWI6SX9Bif76MWJSzmKZsfoeMQ3gnhKZXyEB2xTErBKWmh8snDSntdF67CurJ4uNZlsy1djifFwlWNKUEHSCYQilDrqsazwusSj8YzPHno4-f4ZrW3Ad9EzOI42vdL52P61Z6Ceatc6V43J-gg12WA011so5fb4XQwSu4f78aD_n1iWEa7iYE8fouTTJBUAtfUgjWWmAwAKCykNETQlHOe5taYhZaUCpvl1FjZE1LkvI2ut7qrZrGMs1DV8V618sVS-41yulD_O1Xxpl7dWglO0h4VUeBiJ-DdRwOhVssiGChLXYFrgmKkS0WXspRE9HKLGu9C8JD_rqFEfdujFGNKqGhPhM__HvaL_vjBPwHbWYwc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2041641250</pqid></control><display><type>article</type><title>Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology</title><source>Freely Accessible Journals</source><source>PubMed (Medline)</source><creator>Gholami, Mohammad ; Ravanshad, Mehrdad ; Baesi, Kazem ; Samiee, Siamak M. ; Hosseini Rozbahani, Negin ; Mohraz, Minoo</creator><creatorcontrib>Gholami, Mohammad ; Ravanshad, Mehrdad ; Baesi, Kazem ; Samiee, Siamak M. ; Hosseini Rozbahani, Negin ; Mohraz, Minoo ; Hepatitis andAIDS Department, Pasture Institute of Iran, Tehran, Iran ; Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran ; Food and Drug Laboratory Research Center, Ministry of Health and Medical Education, Tehran, Iran ; Department of Medical Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran ; Iranian Research Center for HIV AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Science, Tehran, Iran</creatorcontrib><description>The human immunodeficiency virus type 1 (HIV-1) is an infectious viral agent that gradually extinguishes the immune system, resulting in acquired immune deficiency syndrome (AIDS). The aim of this study was to construct an RNA-positive control based on armored (AR) RNA technology, using HIV-1 RNA as a model.
The MS2 maturase, a coat protein gene (at positions 1765 to 1787) and HIV-1 pol gene were cloned into pET-32a plasmid. The prepared plasmid was transformed into Escherichia coli strain BL2 (DE3), and the expression of the construct was induced by 1 mM of isopropyl-L-thio-D-galactopyranoside (IPTG) at 37 °C for 16 h to obtain the fabricated AR RNA. The AR RNA was precipitated and purified using polyethylene glycol and Sephacryl S-200 chromatography.
The stability of AR RNA was evaluated by treatment with DNase I and RNase A and confirmed by transmission electron microscopy and gel agarose electrophoresis. Tenfold serial dilution of AR RNA from 101 to 105 was prepared. Real-time PCR assays had a range of detection between 101 and 105. In addition, R2 value was 0.998, and the slope of the standard curve was -3.33.
Prepared AR RNA, as a positive control, could be used as a basis for launching an in-house HIV-1 virus assay and other infectious agents. It can be readily available to laboratories and HIV research centers. The AR RNA is non-infectious and highly resistant to ribonuclease enzyme and can reduce the risk of infection in the clinical laboratory.</description><identifier>ISSN: 1028-852X</identifier><identifier>EISSN: 2008-823X</identifier><identifier>DOI: 10.29252/.22.6.394</identifier><identifier>PMID: 29776310</identifier><language>eng</language><publisher>Iran: Pasteur Institute</publisher><subject>Escherichia coli - genetics ; Escherichia coli - metabolism ; Full Length ; HIV-1 - enzymology ; Humans ; Plasmids - biosynthesis ; Plasmids - genetics ; Plasmids - pharmacology ; Ribonucleases - biosynthesis ; Ribonucleases - genetics ; Ribonucleases - pharmacology ; RNA, Viral - biosynthesis ; RNA, Viral - genetics</subject><ispartof>Iranian biomedical journal, 2018-11, Vol.22 (6), p.394-400</ispartof><rights>Copyright: © Iranian Biomedical Journal 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2914-cef9253096057e3a1dedcd0c9eee1eb77c06153335fdccba7116d9f1cd78676f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305816/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305816/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29776310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gholami, Mohammad</creatorcontrib><creatorcontrib>Ravanshad, Mehrdad</creatorcontrib><creatorcontrib>Baesi, Kazem</creatorcontrib><creatorcontrib>Samiee, Siamak M.</creatorcontrib><creatorcontrib>Hosseini Rozbahani, Negin</creatorcontrib><creatorcontrib>Mohraz, Minoo</creatorcontrib><creatorcontrib>Hepatitis andAIDS Department, Pasture Institute of Iran, Tehran, Iran</creatorcontrib><creatorcontrib>Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran</creatorcontrib><creatorcontrib>Food and Drug Laboratory Research Center, Ministry of Health and Medical Education, Tehran, Iran</creatorcontrib><creatorcontrib>Department of Medical Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran</creatorcontrib><creatorcontrib>Iranian Research Center for HIV AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Science, Tehran, Iran</creatorcontrib><title>Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology</title><title>Iranian biomedical journal</title><addtitle>Iran Biomed J</addtitle><description>The human immunodeficiency virus type 1 (HIV-1) is an infectious viral agent that gradually extinguishes the immune system, resulting in acquired immune deficiency syndrome (AIDS). The aim of this study was to construct an RNA-positive control based on armored (AR) RNA technology, using HIV-1 RNA as a model.
The MS2 maturase, a coat protein gene (at positions 1765 to 1787) and HIV-1 pol gene were cloned into pET-32a plasmid. The prepared plasmid was transformed into Escherichia coli strain BL2 (DE3), and the expression of the construct was induced by 1 mM of isopropyl-L-thio-D-galactopyranoside (IPTG) at 37 °C for 16 h to obtain the fabricated AR RNA. The AR RNA was precipitated and purified using polyethylene glycol and Sephacryl S-200 chromatography.
The stability of AR RNA was evaluated by treatment with DNase I and RNase A and confirmed by transmission electron microscopy and gel agarose electrophoresis. Tenfold serial dilution of AR RNA from 101 to 105 was prepared. Real-time PCR assays had a range of detection between 101 and 105. In addition, R2 value was 0.998, and the slope of the standard curve was -3.33.
Prepared AR RNA, as a positive control, could be used as a basis for launching an in-house HIV-1 virus assay and other infectious agents. It can be readily available to laboratories and HIV research centers. The AR RNA is non-infectious and highly resistant to ribonuclease enzyme and can reduce the risk of infection in the clinical laboratory.</description><subject>Escherichia coli - genetics</subject><subject>Escherichia coli - metabolism</subject><subject>Full Length</subject><subject>HIV-1 - enzymology</subject><subject>Humans</subject><subject>Plasmids - biosynthesis</subject><subject>Plasmids - genetics</subject><subject>Plasmids - pharmacology</subject><subject>Ribonucleases - biosynthesis</subject><subject>Ribonucleases - genetics</subject><subject>Ribonucleases - pharmacology</subject><subject>RNA, Viral - biosynthesis</subject><subject>RNA, Viral - genetics</subject><issn>1028-852X</issn><issn>2008-823X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LAzEQhoMoWqsXf4DkKMLWfHST7kWopdqCqNRaegtpMqsr201Ndgv990ZbRU8zk3nmnQkvQmeUdFjGUnbVYawjOjzr7qEWI6SX9Bif76MWJSzmKZsfoeMQ3gnhKZXyEB2xTErBKWmh8snDSntdF67CurJ4uNZlsy1djifFwlWNKUEHSCYQilDrqsazwusSj8YzPHno4-f4ZrW3Ad9EzOI42vdL52P61Z6Ceatc6V43J-gg12WA011so5fb4XQwSu4f78aD_n1iWEa7iYE8fouTTJBUAtfUgjWWmAwAKCykNETQlHOe5taYhZaUCpvl1FjZE1LkvI2ut7qrZrGMs1DV8V618sVS-41yulD_O1Xxpl7dWglO0h4VUeBiJ-DdRwOhVssiGChLXYFrgmKkS0WXspRE9HKLGu9C8JD_rqFEfdujFGNKqGhPhM__HvaL_vjBPwHbWYwc</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Gholami, Mohammad</creator><creator>Ravanshad, Mehrdad</creator><creator>Baesi, Kazem</creator><creator>Samiee, Siamak M.</creator><creator>Hosseini Rozbahani, Negin</creator><creator>Mohraz, Minoo</creator><general>Pasteur Institute</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201811</creationdate><title>Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology</title><author>Gholami, Mohammad ; Ravanshad, Mehrdad ; Baesi, Kazem ; Samiee, Siamak M. ; Hosseini Rozbahani, Negin ; Mohraz, Minoo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2914-cef9253096057e3a1dedcd0c9eee1eb77c06153335fdccba7116d9f1cd78676f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Escherichia coli - genetics</topic><topic>Escherichia coli - metabolism</topic><topic>Full Length</topic><topic>HIV-1 - enzymology</topic><topic>Humans</topic><topic>Plasmids - biosynthesis</topic><topic>Plasmids - genetics</topic><topic>Plasmids - pharmacology</topic><topic>Ribonucleases - biosynthesis</topic><topic>Ribonucleases - genetics</topic><topic>Ribonucleases - pharmacology</topic><topic>RNA, Viral - biosynthesis</topic><topic>RNA, Viral - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gholami, Mohammad</creatorcontrib><creatorcontrib>Ravanshad, Mehrdad</creatorcontrib><creatorcontrib>Baesi, Kazem</creatorcontrib><creatorcontrib>Samiee, Siamak M.</creatorcontrib><creatorcontrib>Hosseini Rozbahani, Negin</creatorcontrib><creatorcontrib>Mohraz, Minoo</creatorcontrib><creatorcontrib>Hepatitis andAIDS Department, Pasture Institute of Iran, Tehran, Iran</creatorcontrib><creatorcontrib>Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran</creatorcontrib><creatorcontrib>Food and Drug Laboratory Research Center, Ministry of Health and Medical Education, Tehran, Iran</creatorcontrib><creatorcontrib>Department of Medical Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran</creatorcontrib><creatorcontrib>Iranian Research Center for HIV AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Science, Tehran, Iran</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Iranian biomedical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gholami, Mohammad</au><au>Ravanshad, Mehrdad</au><au>Baesi, Kazem</au><au>Samiee, Siamak M.</au><au>Hosseini Rozbahani, Negin</au><au>Mohraz, Minoo</au><aucorp>Hepatitis andAIDS Department, Pasture Institute of Iran, Tehran, Iran</aucorp><aucorp>Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran</aucorp><aucorp>Food and Drug Laboratory Research Center, Ministry of Health and Medical Education, Tehran, Iran</aucorp><aucorp>Department of Medical Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran</aucorp><aucorp>Iranian Research Center for HIV AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Science, Tehran, Iran</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology</atitle><jtitle>Iranian biomedical journal</jtitle><addtitle>Iran Biomed J</addtitle><date>2018-11</date><risdate>2018</risdate><volume>22</volume><issue>6</issue><spage>394</spage><epage>400</epage><pages>394-400</pages><issn>1028-852X</issn><eissn>2008-823X</eissn><abstract>The human immunodeficiency virus type 1 (HIV-1) is an infectious viral agent that gradually extinguishes the immune system, resulting in acquired immune deficiency syndrome (AIDS). The aim of this study was to construct an RNA-positive control based on armored (AR) RNA technology, using HIV-1 RNA as a model.
The MS2 maturase, a coat protein gene (at positions 1765 to 1787) and HIV-1 pol gene were cloned into pET-32a plasmid. The prepared plasmid was transformed into Escherichia coli strain BL2 (DE3), and the expression of the construct was induced by 1 mM of isopropyl-L-thio-D-galactopyranoside (IPTG) at 37 °C for 16 h to obtain the fabricated AR RNA. The AR RNA was precipitated and purified using polyethylene glycol and Sephacryl S-200 chromatography.
The stability of AR RNA was evaluated by treatment with DNase I and RNase A and confirmed by transmission electron microscopy and gel agarose electrophoresis. Tenfold serial dilution of AR RNA from 101 to 105 was prepared. Real-time PCR assays had a range of detection between 101 and 105. In addition, R2 value was 0.998, and the slope of the standard curve was -3.33.
Prepared AR RNA, as a positive control, could be used as a basis for launching an in-house HIV-1 virus assay and other infectious agents. It can be readily available to laboratories and HIV research centers. The AR RNA is non-infectious and highly resistant to ribonuclease enzyme and can reduce the risk of infection in the clinical laboratory.</abstract><cop>Iran</cop><pub>Pasteur Institute</pub><pmid>29776310</pmid><doi>10.29252/.22.6.394</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1028-852X |
ispartof | Iranian biomedical journal, 2018-11, Vol.22 (6), p.394-400 |
issn | 1028-852X 2008-823X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6305816 |
source | Freely Accessible Journals; PubMed (Medline) |
subjects | Escherichia coli - genetics Escherichia coli - metabolism Full Length HIV-1 - enzymology Humans Plasmids - biosynthesis Plasmids - genetics Plasmids - pharmacology Ribonucleases - biosynthesis Ribonucleases - genetics Ribonucleases - pharmacology RNA, Viral - biosynthesis RNA, Viral - genetics |
title | Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA Technology |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A19%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preparation%20and%20Evaluation%20of%20Ribonuclease-Resistant%20Viral%20HIV%20RNA%20Standards%20Based%20on%20Armored%20RNA%20Technology&rft.jtitle=Iranian%20biomedical%20journal&rft.au=Gholami,%20Mohammad&rft.aucorp=Hepatitis%20andAIDS%20Department,%20Pasture%20Institute%20of%20Iran,%20Tehran,%20Iran&rft.date=2018-11&rft.volume=22&rft.issue=6&rft.spage=394&rft.epage=400&rft.pages=394-400&rft.issn=1028-852X&rft.eissn=2008-823X&rft_id=info:doi/10.29252/.22.6.394&rft_dat=%3Cproquest_pubme%3E2041641250%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2914-cef9253096057e3a1dedcd0c9eee1eb77c06153335fdccba7116d9f1cd78676f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2041641250&rft_id=info:pmid/29776310&rfr_iscdi=true |